Physician profile
Michael Brit
NPI 1689692998
$8,944.45
in general payments reported to CMS, 2019-2025
31 companies · $1,909 in 2025
The $1,909 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $435 · 2021: $641 · 2022: $1,796 · 2023: $1,513 · 2024: $2,107 · 2025: $1,909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,432 · Education: $96.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,431.95 |
| Education | $96.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,920.05 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $1,125.29 | 2020-2025 | |
| Janssen Biotech, INC. | $931.22 | 2019-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $743.81 | 2019-2025 | Cimzia, Bimzelx |
| Amgen INC. | $691.75 | 2020-2025 | Enbrel, Otezla, Evenity |
| Pfizer INC. | $576.37 | 2019-2025 | |
| Glaxosmithkline, LLC. | $416.12 | 2020-2025 | Benlysta |
| Astrazeneca Pharmaceuticals Lp | $328.81 | 2022-2025 | Saphnelo, Wainua |
| E.R. Squibb & Sons, L.L.C. | $277.69 | 2021-2025 | Orencia |
| Lilly USA, LLC | $260.55 | 2019-2023 | Taltz |
| Sandoz INC. | $254.65 | 2024-2025 | Hyrimoz |
| Aurinia Pharma U.S., INC. | $166.50 | 2021-2022 | |
| Radius Health, INC. | $161.35 | 2020-2025 | Tymlos |
| Mallinckrodt Hospital Products INC. | $151.19 | 2022-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.78 | 2023-2024 | Cyltezo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $101.24 | 2019-2025 | Strensiq |
| Genzyme Corporation | $93.40 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $89.43 | 2024 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $75.18 | 2023-2024 | Idacio |
| Genentech USA, INC. | $72.45 | 2019-2024 | Actemra |
| Organon LLC | $59.30 | 2024-2025 | Hadlima, Nexplanon |
| Horizon Therapeutics Plc | $58.32 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $51.58 | 2023-2024 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $48.68 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $35.20 | 2019 | |
| Sobi, INC | $23.36 | 2024 | |
| Celltrion USA INC. | $19.38 | 2023 | Yuflyma |
| Regeneron Healthcare Solutions, INC. | $19.02 | 2024 | Evkeeza |
| Kiniksa Pharmaceuticals, Ltd. | $17.94 | 2023 | Arcalyst |
| Scilex Pharmaceuticals INC. | $17.36 | 2024 | |
| Kyowa Kirin, INC. | $14.48 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.